{"id":"https://openalex.org/W4389029458","doi":"https://doi.org/10.1093/ofid/ofad500.1431","title":"1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results","display_name":"1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results","publication_year":2023,"publication_date":"2023-11-27","ids":{"openalex":"https://openalex.org/W4389029458","doi":"https://doi.org/10.1093/ofid/ofad500.1431"},"language":"en","primary_location":{"id":"doi:10.1093/ofid/ofad500.1431","doi":"https://doi.org/10.1093/ofid/ofad500.1431","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofad500.1431","pdf_url":"https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1431/53770468/ofad500.1431.pdf","source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1431/53770468/ofad500.1431.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008971359","display_name":"Onyema Eberechukwu Ogbuagu","orcid":"https://orcid.org/0000-0001-7342-2608","observed_orcids":["https://orcid.org/0000-0001-7342-2608"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Onyema Ogbuagu","raw_affiliation_strings":["Yale School of Medicine , Cheshire, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale School of Medicine , Cheshire, Connecticut","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103806974","display_name":"Edwin DeJesus","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I106165777","display_name":"University of Central Florida","ror":"https://ror.org/036nfer12","country_code":"US","type":"education","lineage":["https://openalex.org/I106165777"]},{"id":"https://openalex.org/I4210120784","display_name":"Orlando Immunology Center","ror":"https://ror.org/02cj88v79","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210120784"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edwin DeJesus","raw_affiliation_strings":["Orlando Immunology Center, University of Central Florida College of Medicine , Orlando, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orlando Immunology Center, University of Central Florida College of Medicine , Orlando, FL","institution_ids":["https://openalex.org/I106165777","https://openalex.org/I4210120784"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042462726","display_name":"Mezgebe Berhe","orcid":"https://orcid.org/0000-0002-7287-567X","observed_orcids":["https://orcid.org/0000-0002-7287-567X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mezgebe Berhe","raw_affiliation_strings":["North Texas Infectious Diseases Consultants , Dallas, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"North Texas Infectious Diseases Consultants , Dallas, Texas","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036087352","display_name":"Gary J. Richmond","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210109487","display_name":"Broward Health Medical Center","ror":"https://ror.org/01jj2sr90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210109487","https://openalex.org/I4210161735"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary J Richmond","raw_affiliation_strings":["Broward Health Medical Center , Fort Lauderdale, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Broward Health Medical Center , Fort Lauderdale, Florida","institution_ids":["https://openalex.org/I4210109487"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089993955","display_name":"Peter Jerome Ruane","orcid":"https://orcid.org/0000-0002-7170-9928","observed_orcids":["https://orcid.org/0000-0002-7170-9928"]},"institutions":[{"id":"https://openalex.org/I4210148755","display_name":"Ruane Medical","ror":"https://ror.org/05prbcv50","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210148755"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter J Ruane","raw_affiliation_strings":["Ruane Clinical Research , Los Angeles, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ruane Clinical Research , Los Angeles, California","institution_ids":["https://openalex.org/I4210148755"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029977496","display_name":"Gary Ian Sinclair","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gary I Sinclair","raw_affiliation_strings":["PrismHealth NTX , Dallas, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PrismHealth NTX , Dallas, Texas","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069170911","display_name":"Moti N. Ramgopal","orcid":"https://orcid.org/0000-0001-7448-1976","observed_orcids":["https://orcid.org/0000-0001-7448-1976"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Moti N Ramgopal","raw_affiliation_strings":["Midway Immunology & Research Center , Fort Pierce, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Midway Immunology & Research Center , Fort Pierce, Florida","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110204338","display_name":"William E. Sanchez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Sanchez","raw_affiliation_strings":["Floridian Clinical Research , Miami Lakes, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Floridian Clinical Research , Miami Lakes, Florida","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091909943","display_name":"Gordon E. Crofoot","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gordon E Crofoot","raw_affiliation_strings":["The Crofoot Research Center , Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Crofoot Research Center , Houston, Texas","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051466983","display_name":"Nicolas Margot","orcid":"https://orcid.org/0000-0002-0911-4237","observed_orcids":["https://orcid.org/0000-0002-0911-4237"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicolas A Margot","raw_affiliation_strings":["Gilead Sciences Inc , Foster City, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences Inc , Foster City, California","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Hui Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hui Wang","raw_affiliation_strings":["Gilead Sciences Inc. , Foster City, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences Inc. , Foster City, California","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027618515","display_name":"Hadas Dvory\u2010Sobol","orcid":"https://orcid.org/0000-0003-0716-2750","observed_orcids":["https://orcid.org/0000-0003-0716-2750"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hadas Dvory-Sobol","raw_affiliation_strings":["Gilead Sciences , Foster City, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences , Foster City, California","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109947281","display_name":"Martin S. Rhee","orcid":"https://orcid.org/0000-0001-5263-9613","observed_orcids":["https://orcid.org/0000-0001-5263-9613"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Rhee","raw_affiliation_strings":["Gilead Sciences , Foster City, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences , Foster City, California","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064486492","display_name":"Jared M. Baeten","orcid":"https://orcid.org/0000-0001-8242-8438","observed_orcids":["https://orcid.org/0000-0001-8242-8438"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jared Baeten","raw_affiliation_strings":["Gilead Sciences , Foster City, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences , Foster City, California","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5035340318","display_name":"Sorana Segal\u2010Maurer","orcid":"https://orcid.org/0009-0000-1113-4977","observed_orcids":["https://orcid.org/0009-0000-1113-4977"]},"institutions":[{"id":"https://openalex.org/I2801107848","display_name":"New York Hospital Queens","ror":"https://ror.org/01j17xg39","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801107848"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sorana Segal-Maurer","raw_affiliation_strings":["Division of Infectious Diseases , New York\u2013Presbyterian Queens, Flushing, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Infectious Diseases , New York\u2013Presbyterian Queens, Flushing, New York","institution_ids":["https://openalex.org/I2801107848"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3676,"currency":"USD","value_usd":3676},"apc_paid":{"value":3676,"currency":"USD","value_usd":3676},"fwci":1.235,"has_fulltext":true,"cited_by_count":6,"citation_normalized_percentile":{"value":0.78582088,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"10","issue":"Supplement_2","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lenacapavir","display_name":"lenacapavir","score":0.9980000257492065},{"id":"https://openalex.org/keywords/long-acting-antiretroviral-therapy","display_name":"long-acting antiretroviral therapy","score":0.8500000238418579},{"id":"https://openalex.org/keywords/viral-suppression","display_name":"viral suppression","score":0.5400000214576721},{"id":"https://openalex.org/keywords/cd4-count-recovery","display_name":"CD4 count recovery","score":0.7670000195503235},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.44699999690055847},{"id":"https://openalex.org/keywords/long-term-efficacy","display_name":"long-term efficacy","score":0.31700000166893005}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8683240413665771},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.7267323136329651},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.5165680646896362},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5064715147018433},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.4717812240123749},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4652232825756073},{"id":"https://openalex.org/C2778451633","wikidata":"https://www.wikidata.org/wiki/Q5629934","display_name":"HIV drug resistance","level":5,"score":0.4401338994503021},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.4268476366996765},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3218584954738617},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.28456592559814453},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2484985589981079},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1093/ofid/ofad500.1431","doi":"https://doi.org/10.1093/ofid/ofad500.1431","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofad500.1431","pdf_url":"https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1431/53770468/ofad500.1431.pdf","source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10677747","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10677747","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10677747/pdf/ofad500.1431.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infect Dis","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1093/ofid/ofad500.1431","doi":"https://doi.org/10.1093/ofid/ofad500.1431","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofad500.1431","pdf_url":"https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1431/53770468/ofad500.1431.pdf","source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4389029458.pdf","grobid_xml":"https://content.openalex.org/works/W4389029458.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4311737282","https://openalex.org/W4406954601","https://openalex.org/W4417517450","https://openalex.org/W4402001825","https://openalex.org/W4383894396","https://openalex.org/W4406911700","https://openalex.org/W4295088440","https://openalex.org/W7122630190","https://openalex.org/W4280564133","https://openalex.org/W4406956490"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Lenacapavir":[2],"(LEN)":[3],"is":[4,34],"a":[5,199],"highly":[6],"potent,":[7],"long-acting,":[8],"first-in-class":[9],"inhibitor":[10],"of":[11,18,171,212,240,251,338,342],"HIV-1":[12,19,45,120,148,160,191,313],"capsid":[13],"protein":[14],"for":[15,52,166,340],"the":[16,70,79,140,210,336],"treatment":[17,316,341],"infection":[20],"in":[21,27,40,59,98,139,319],"adults":[22],"with":[23,29,44,46,214,311,321,344],"multidrug":[24],"resistance":[25,235],"(MDR)":[26],"combination":[28,320],"other":[30,168],"antiretrovirals.":[31],"Methods":[32],"CAPELLA":[33],"an":[35,62,278,322],"ongoing,":[36],"phase":[37],"2/3":[38],"study":[39,181],"heavily":[41],"treatment-experienced":[42],"people":[43,310,343],"multidrug-resistance.":[47],"Participants":[48],"received":[49],"oral":[50],"LEN":[51,57,234,254,318,339],"loading":[53],"followed":[54],"by":[55,198],"subcutaneous":[56],"Q6M":[58],"addition":[60],"to":[61,83,122,137,204,207,225,263,277],"investigator-selected":[63],"optimized":[64],"background":[65],"regimen":[66],"(OBR).":[67],"After":[68],"reporting":[69],"efficacy":[71,172],"and":[72,117,156,209,290,294,314,327],"safety":[73],"data":[74,177,334],"through":[75],"52":[76,110],"weeks":[77],"(W),":[78],"protocol":[80],"was":[81,109,255,324],"amended":[82],"allow":[84],"longer":[85],"follow":[86],"up;":[87],"we":[88],"report":[89],"W104":[90],"results.":[91],"Results":[92],"Of":[93],"72":[94],"participants":[95,213,231],"enrolled":[96],"(36":[97],"each":[99,299],"cohort),":[100],"25%":[101],"were":[102,105,179,292,305],"female,":[103],"38%":[104],"Black,":[106],"median":[107,200,248],"age":[108],"years,":[111],"64%":[112],"had":[113,119,147,159,175,190,232],"CD4":[114,195,215],"<200":[115],"cells/\u00b5L,":[116],"46%":[118],"resistant":[121],"all":[123],"4":[124],"major":[125],"classes":[126],"(NRTI,":[127],"NNRTI,":[128],"PI,":[129],"INSTI).":[130],"One":[131,259],"participant":[132,260,274],"(of":[133],"72)":[134],"decided":[135],"not":[136],"continue":[138],"post-W52":[141],"extension.":[142],"At":[143],"W104,":[144],"62%":[145],"(44/71)":[146],"RNA":[149,161,192],"<50":[150,193],"c/mL":[151],"via":[152],"FDA":[153],"Snapshot":[154],"algorithm,":[155],"14%":[157],"(10/71)":[158],">50":[162],"c/mL;":[163],"24%":[164],"discontinued":[165,261,275],"reasons":[167],"than":[169],"lack":[170],"(13/71)":[173],"or":[174],"missing":[176],"but":[178],"on":[180,253],"drug":[182],"(4/71).":[183],"When":[184],"analyzed":[185],"as":[186],"missing=excluded,":[187],"81%":[188],"(44/54)":[189],"c/mL.":[194],"count":[196,216],"increased":[197,219],"97":[201],"cells/\u00b5L":[202,218],"(Q1":[203],"Q3:":[205],"18":[206],"224)":[208],"proportion":[211],"\u2265200":[217],"from":[220],"36%":[221],"(26/72)":[222],"at":[223,228,267,331],"baseline":[224],"71%":[226],"(39/55)":[227],"W104.":[229,332],"Fourteen":[230],"emergent":[233],"(9":[236],"previously":[237,271],"reported),":[238],"6":[239],"whom":[241],"subsequently":[242],"suppressed":[243],"while":[244],"continuing":[245],"LEN.":[246],"The":[247],"(Q1\u2013Q3)":[249],"duration":[250],"follow-up":[252],"125":[256],"(111\u2013140)":[257],"weeks.":[258],"due":[262,276],"injection":[264,286],"site":[265,287],"nodule":[266],"W52":[268],"(Grade":[269],"1,":[270],"reported);":[272],"no":[273],"AE":[279],"after":[280],"W52.":[281],"Most":[282],"common":[283],"AEs":[284],"(excluding":[285],"reactions":[288],"[ISRs]":[289],"COVID-19)":[291],"diarrhea":[293],"nausea":[295],"(19%":[296],"each,":[297],"+5%":[298],"since":[300],"W52,":[301],"respectively).":[302],"LEN-related":[303],"ISRs":[304],"mostly":[306],"mild-to-moderate.":[307],"Conclusion":[308],"In":[309],"MDR":[312,345],"limited":[315],"options,":[317],"OBR":[323],"well":[325],"tolerated":[326],"maintained":[328],"virologic":[329],"suppression":[330],"These":[333],"support":[335],"use":[337],"HIV-1.":[346],"Disclosures":[347],"Onyema":[348],"Ogbuagu,":[349],"MD,":[350,362,371,382,399,409,435,451,465,505,515,526],"Gilead":[351,363,373,383,400,452,466,476,486,496,506,517,527],"Sciences,":[352,355,364,374,384,401,438,441,453,467,477,480,487,490,497,500,507,510,518,521,528,531],"Inc:":[353,356,365,375,385,402,439,442,454,468,478,481,488,491,498,501,508,511,519,522,529,532],"Advisor/Consultant|Gilead":[354,440,530],"Honoraria|Janssen:":[357,443,533],"Advisor/Consultant|Viiv:":[358,403,404,446,447,538],"Advisor/Consultant":[359],"Edwin":[360],"DeJesus,":[361],"Advisor/Consultant|Theratechnology:":[366,367],"Honoraria":[368,405,431,448,539],"Mezgebe":[369],"Berhe,":[370],"MPH,":[372],"Clinical":[376,469],"Trial":[377,470],"Investigator":[378,471],"Gary":[379,406],"J":[380,397],"Richmond,":[381],"Grant/Research":[386,390,392,394,411,414,417,421,425,429,455,457,460],"Support|Glaxo":[387],"Smith":[388],"Kline:":[389],"Support|Insmed:":[391],"Support|TaiMed:":[393],"Support":[395,461],"Peter":[396],"Ruane,":[398],"I.":[407],"Sinclair,":[408],"Abbvie:":[410,436],"Support|Gilead:":[412],"Advisor/Consultant|Gilead:":[413],"Support|Janssen:":[415,418],"Advisor/Consultant|Janssen:":[416,444,534],"Honoraria|Merck:":[419,445],"Advisor/Consultant|Merck:":[420,459],"Support|Merck:":[422,458],"Honoraria|Thera:":[423],"Advisor/Consultant|Thera:":[424],"Support|Thera:":[426],"Honoraria|ViiV:":[427],"Advisor/Consultant|ViiV:":[428],"Support|ViiV:":[430],"Moti":[432],"N":[433],"Ramgopal,":[434],"Honoraria|Gilead":[437],"William":[449],"Sanchez,":[450],"Support|GSK:":[456],"Gordon":[462],"E":[463],"Crofoot,":[464],"Nicolas":[472],"A":[473],"Margot,":[474],"MA,":[475],"Employee|Gilead":[479,489,499,509,520],"Stocks/Bonds":[482,492,502,512,523],"Hui":[483],"Wang,":[484],"PhD,":[485,495,516],"Hadas":[493],"Dvory-Sobol,":[494],"Martin":[503],"Rhee,":[504],"Jared":[513],"Baeten,":[514],"Sorana":[524],"Segal-Maurer,":[525],"Honoraria|Theratechnologies:":[535],"Advisor/Consultant|Theratechnologies:":[536],"Honoraria|Viiv:":[537]},"counts_by_year":[{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2023-11-27T00:00:00"}